Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash & Equivalents (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash & Equivalents for 16 consecutive years, with $150.9 million as the latest value for Q1 2025.

  • On a quarterly basis, Cash & Equivalents fell 47.67% to $150.9 million in Q1 2025 year-over-year; TTM through Mar 2025 was $150.9 million, a 47.67% decrease, with the full-year FY2024 number at $166.7 million, up 217.58% from a year prior.
  • Cash & Equivalents was $150.9 million for Q1 2025 at Standard Biotools, down from $166.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $288.3 million in Q1 2024 to a low of $29.5 million in Q4 2021.
  • A 5-year average of $110.1 million and a median of $80.4 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 58.66% in 2021, then soared 269.23% in 2023.
  • Standard Biotools' Cash & Equivalents stood at $29.5 million in 2021, then surged by 179.38% to $82.3 million in 2022, then crashed by 36.23% to $52.5 million in 2023, then skyrocketed by 217.58% to $166.7 million in 2024, then fell by 9.51% to $150.9 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cash & Equivalents are $150.9 million (Q1 2025), $166.7 million (Q4 2024), and $211.9 million (Q3 2024).